Publications — Radcliffe Department of Medicine

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment.

Pellagatti A. and Boultwood J., (2022), Adv Biol Regul

Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations.

Choudhary GS. et al, (2022), Elife, 11

Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q.

Adema V. et al, (2022), EBioMedicine, 80

PRELIMINARY PROSPECTIVE MOLECULAR ANALYSIS OF PLCBETA1 AND PLCGAMMA2 IN MDS PATIENTS TREATED WITH AZACITIDINE AND VENETOCLAX

De Stefano A. et al, (2022), HAEMATOLOGICA, 107, 65 - 65

BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome.

Gorombei P. et al, (2021), Int J Mol Sci, 22

ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine

Rahmani NE. et al, (2021), Blood Cancer Journal, 11

Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

Bernard E. et al, (2021), Nat Med, 27

MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism.

Ueda K. et al, (2021), Cancer Cell

Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

Bernard E. et al, (2021), Nat Med, 27

The utilisation of glutamine and glucose by a 3-D tumour model trapped in quiescence.

Smith H. et al, (2021), Int J Biochem Cell Biol

SF3B1 mutant myelodysplastic syndrome: Recent advances.

Pellagatti A. and Boultwood J., (2020), Adv Biol Regul

Azacitidine and Lenalidomide in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study and Impact of Cytogenetic Scores and Mutational Status on Long-Lasting Responses

Finelli C. et al, (2020), BLOOD, 136

Sequential Analysis of miRNA Profiling during Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes

Follo MY. et al, (2020), BLOOD, 136

DEFERASIROX TARGETS PHOSPHOLIPASE C BETA1 SIGNALING IN MYELODYSPLASTIC SYNDROMES (MDS)

Follo MY. et al, (2020), HAEMATOLOGICA, 105, S63 - S63

Spliceosome mutations: 1 plus 1 does not always equal 2.

Pellagatti A. and Boultwood J., (2020), Blood, 136, 1471 - 1472

Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS).

Cappellini A. et al, (2020), FASEB J

SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications.

Singh S. et al, (2020), Leukemia, 34, 2525 - 2530

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

Bernard E. et al, (2020), Nat Med

SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.

Malcovati L. et al, (2020), Blood, 136, 157 - 170

Splicing factor mutant myelodysplastic syndromes: Recent advances.

Pellagatti A. and Boultwood J., (2020), 75

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?